Torsten Dreier
Plus aucun poste en cours
Profil
Torsten Dreier is the founder of argenx SE, which was founded in 2008.
He held the title of Chief Development Officer.
Dr. Dreier's former jobs include Director-Therapeutic Drug Development at Ablynx NV, Principal at The Scripps Research Institute, and Scientist at Micromet AG.
Dr. Dreier received a graduate and doctorate degree from Eberhard Karls Universität Tübingen.
Anciens postes connus de Torsten Dreier
| Sociétés | Poste | Fin |
|---|---|---|
The Scripps Research Institute
 The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California. | Corporate Officer/Principal | - |
| ARGENX SE | Founder | - |
Micromet AG
 Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany. | Corporate Officer/Principal | - |
| ABLYNX | Corporate Officer/Principal | - |
Formation de Torsten Dreier
| Eberhard Karls Universität Tübingen | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ARGENX SE | Health Technology |
| Entreprise privées | 2 |
|---|---|
Micromet AG
Micromet AG Pharmaceuticals: MajorHealth Technology Micromet AG developed, manufactured and marketed novel antibody derived therapeutics for the treatment and control of cancer, inflammatory and autoimmune diseases. It's goal was to commercialize products in these indication areas that have significant unmet medical needs. Founded in 1993, the company was headquartered in Munich, Germany. | Health Technology |
Ablynx NV
 Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
